Literature DB >> 2165103

A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection.

J J Gibson1, C A Hornung, G R Alexander, F K Lee, W A Potts, A J Nahmias.   

Abstract

Occurrence rates and determinants of infection with herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) were measured in first- and fourth-year undergraduate students at a state university. This cross-sectional multistage probability sample survey included sociodemographic characteristics, sexual behavior patterns, disease history, and HSV type-specific antibody status. The prevalence of HSV-1 antibody was 37.2% in freshmen and 46.1% in fourth-year students; that for HSV-2 antibody was 0.4% and 4.3%, respectively. A history of cold sores was obtained in 25.6% of the freshmen; none had a history of manifest genital herpes. A history of cold sores was obtained in 28% and a history of genital herpes in 1.1% of the fourth-year students. The case-weighted prevalence of HSV-1 and HSV-2 antibodies was found to be significantly elevated for a number of student characteristics. However, multiple logistic regression analyses indicated that the significant predictors of HSV-1 antibodies in this population were female gender, black race, first intercourse at age less than or equal to 15 years, total years of sexual activity, history of a partner with oral sores, and a personal history of a non-HSV sexually transmitted disease (STD). Predictors of HSV-2 antibody were black race, duration of sexual activity, and history of a non-HSV STD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165103     DOI: 10.1093/infdis/162.2.306

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Comparative performance of herpes simplex virus type 1-specific serologic assays from MRL and Meridian Diagnostics.

Authors:  Julie A Ribes; Angela Smith; Marie Hayes; Doris J Baker; Jeffrey L Winters
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Incidence and management of oral conditions in general practice.

Authors:  S Deconinck; A J P Boeke; I van der Waal; Daniëlle A van der Windt
Journal:  Br J Gen Pract       Date:  2003-02       Impact factor: 5.386

3.  Herpes simplex type 2 infection in a cohort aged 21 years.

Authors:  J Eberhart-Phillips; N P Dickson; C Paul; J P Fawcett; D Holland; J Taylor; A L Cunningham
Journal:  Sex Transm Infect       Date:  1998-06       Impact factor: 3.519

4.  Sexual and demographic risk factors for herpes simplex type 1 and 2 in women attending an antenatal clinic.

Authors:  R L Tideman; J Taylor; C Marks; C Seifert; G Berry; B Trudinger; A Cunningham; A Mindel
Journal:  Sex Transm Infect       Date:  2001-12       Impact factor: 3.519

5.  Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population.

Authors:  J A Ribes; A D Steele; J P Seabolt; D J Baker
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

6.  Predominance of herpes simplex virus type 1 from patients with genital herpes in Nova Scotia.

Authors:  Kevin R Forward; Spencer Hs Lee
Journal:  Can J Infect Dis       Date:  2003-03

Review 7.  Genital herpes: review of the epidemic and potential use of type-specific serology.

Authors:  R L Ashley; A Wald
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

8.  Risk profiles for genital infection in women.

Authors:  B A Evans; T Tasker; K D MacRae
Journal:  Genitourin Med       Date:  1993-08

9.  A comparison of sexual behaviour and risk behaviour for HIV infection between women in three clinical settings.

Authors:  K W Radcliffe; T Tasker; B A Evans; A Bispham; M Snelling
Journal:  Genitourin Med       Date:  1993-12

Review 10.  Herpes simplex virus infections of women and their offspring: implications for a developed society.

Authors:  R J Whitley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.